NFKB1 and atherosclerosis: During inhibition of NF-κB, Marchesi et al. [15] reported reduced expression of IL-6, VCAM-1, and MCP-1, and ACE inhibitor treatment also reduced NF-κB activity, thereby preventing vascular inflammatory stimulation that is associated with atherosclerosis [15].